Full Press Release Details
Lexicon to Present Study Results Relating to LX9211 and INPEFA™ (Sotagliflozin) at the American Diabetes Association's 83rd Scientific Sessions.
LXRX
Lexicon to Present Study Results Relating to LX9211 and INPEFA™ (Sotagliflozin) at the American Diabetes Association's 83rd Scientific Sessions
Key Takeaway: Lexicon to Present Study Results Relating to LX9211 and INPEFA™ (Sotagliflozin) at the American Diabetes Association's 83rd Scientific Sessions
Price reaction · baseline $2.42 (2023-06-16 close) · hit after-hours · 1 other LXRX headline(s) in the window, move may be shared
day 0 close · peak
-2.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus